Heat shock protein 90 - A potential target in the treatment of human acute myelogenous leukemia

Current Cancer Drug Targets

Volumn 9, Issue 6, 2009, Pages 761-776

  Reikvam, H ^a   Ersvaer E ^a   Bruserud, O ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute myelogenous leukemia; Apoptosis; Chaperone; Client proteins; Heat shock protein; Heat shock protein 90 inhibitors

Indexed keywords

ACTIVATOR OF HSP90 ATPASE 1; ADENOSINE TRIPHOSPHATE; ALVESPIMYCIN; ANTILEUKEMIC AGENT; AT 13387; AT 14487; BENZOQUINON ANSAMYCINE; BENZOQUINONE DERIVATIVE; CELL CYCLE PROTEIN 37; CHAPERONE; CNF 2024; CUDC 0305; CYCLOPHILIN 40; FK506 BINDING PROTEIN 52; GELDANAMYCIN; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HERBIMYCIN; HISTONE DEACETYLASE INHIBITOR; HSP ORGANIZING PROTEIN; IPI 493; MPC 3100; NVP AUY 922; P23; PROTEIN PHOSPHATASE 5; RADICICOL; RETASPIMYCIN; SNX 5422; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 888;

ABDOMINAL PAIN; ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; AMINO TERMINAL SEQUENCE; ANOREXIA; ANTIGEN PRESENTATION; APOPTOSIS; AREA UNDER THE CURVE; AUTOPHAGY; B LYMPHOCYTE; BINDING SITE; CANCER CELL CULTURE; CANCER RELAPSE; CANCER RESISTANCE; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CRYSTAL STRUCTURE; DENDRITIC CELL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SOLUBILITY; ENZYME INHIBITION; FATIGUE; HEADACHE; HUMAN; HYDROLYSIS; IMMUNE SYSTEM; LEUKEMOGENESIS; LIVER TOXICITY; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; PANCREATITIS; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION; TREATMENT FAILURE; UBIQUITINATION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; AUTOPHAGY; CELL CYCLE; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSION; LEUKEMIA, MYELOID, ACUTE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS;

EID: 70349300539     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909789271486     Document Type: Review

References (153)

1. Smith, M.; Barnett, M.; Bassan, R.; Gatta, G.; Tondini, C.; Kern, W. Adult acute myeloid leukaemia. Crit. Rev. Oncol. Hematol. 2004, 50, 197-222.
2. Wang, Z. Y.; Chen, Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111, 2505-2515.
3. Latagliata, R.; Bongarzoni, V.; Carmosino, I.; Mengarelli, A.; Breccia, M.; Borza, P. A.; D'Andrea, M.; D'Elia, G. M.; Mecarocci, S.; Morano, S. G.; Petti, M. C.; Mandelli, F.; Alimena, G. Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. Ann. Oncol. 2006, 17, 281-285. (Pubitemid 43167924)
4. Ryningen, A.; Stapnes, C.; Lassalle, P.; Corbascio, M.; Gjertsen, B. T.; Bruserud, O. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and alltrans retinoic acid. Leuk. Res. 2009, 33, 779-787.
5. Valk, P. J.; Verhaak, R. G.; Beijen, M. A.; Erpelinck, C. A.; Barjesteh van Waalwijk van Doorn-Khosrovani, S.; Boer, J. M.; Beverloo, H. B.; Moorhouse, M. J.; van der Spek, P. J.; Lowenberg, B.; Delwel, R. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 2004, 350, 1617-1628.
6. Saibil, H. R. Chaperone machines in action. Curr. Opin. Struct. Biol. 2008, 18, 35-42.
7. Lanneau, D.; Brunet, M.; Frisan, E.; Solary, E.; Fontenay, M.; Garrido, C. Heat shock proteins: essential proteins for apoptosis regulation. J. Cell Mol. Med. 2008, 12, 743-761.
8. Barginear, M. F.; Van Poznak, C.; Rosen, N.; Modi, S.; Hudis, C. A.; Budman, D. R. The heat shock protein 90 chaperone complex: an evolving therapeutic target. Curr. Cancer Drug Targets 2008, 8, 522-532.
9. Burdon, R. H. Heat shock and the heat shock proteins. Biochem. J. 1986, 240, 313-324.
10. Shamovsky, I.; Nudler, E. New insights into the mechanism of heat shock response activation. Cell Mol. Life Sci. 2008, 65, 855-861.
11. Dezwaan, D. C.; Freeman, B. C. HSP90: the Rosetta stone for cellular protein dynamics? Cell Cycle 2008, 7, 1006-1012.
12. Burger, A. M.; Seth, A. K. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur. J. Cancer 2004, 40, 2217-2229.
13. Caplan, A. J.; Mandal, A. K.; Theodoraki, M. A. Molecular chaperones and protein kinase quality control. Trends Cell Biol. 2007, 17, 87-92. (Pubitemid 46199182)
14. Lindquist, S.; Craig, E. A. The heat-shock proteins. Annu. Rev. Genet. 1988, 22, 631-677.
15. Mathew, A.; Mathur, S. K.; Jolly, C.; Fox, S. G.; Kim, S.; Morimoto, R. I. Stress-specific activation and repression of heat shock factors 1 and 2. Mol. Cell Biol. 2001, 21, 7163-7171. (Pubitemid 32953470)
16. Morimoto, R. I. Cells in stress: transcriptional activation of heat shock genes. Science 1993, 259, 1409-1410. (Pubitemid 23101373)
17. Zou, J.; Guo, Y.; Guettouche, T.; Smith, D. F.; Voellmy, R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998, 94, 471-480.
18. Guettouche, T.; Boellmann, F.; Lane, W. S.; Voellmy, R. Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress. BMC Biochem. 2005, 6, 4. (Pubitemid 40629479)
19. Jolly, C.; Morimoto, R.; Robert-Nicoud, M.; Vourc'h, C. HSF1 transcription factor concentrates in nuclear foci during heat shock: relationship with transcription sites. J. Cell Sci. 1997, 110(Pt 23), 2935-2941.
20. Voellmy, R. On mechanisms that control heat shock transcription factor activity in metazoan cells. Cell Stress Chaperones 2004, 9, 122-133. (Pubitemid 39013809)
21. Tang, D.; Khaleque, M. A.; Jones, E. L.; Theriault, J. R.; Li, C.; Wong, W. H.; Stevenson, M. A.; Calderwood, S. K. Expression of heat shock proteins and heat shock protein messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo. Cell Stress Chaperones 2005, 10, 46-58.
22. Hatfield, K.; Ryningen, A.; Corbascio, M.; Bruserud, O. Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. Int. J. Cancer 2006, 119, 2313-2321. (Pubitemid 44546950)
23. Huston, A.; Leleu, X.; Jia, X.; Moreau, A. S.; Ngo, H. T.; Runnels, J.; Anderson, J.; Alsayed, Y.; Roccaro, A.; Vallet, S.; Hatjiharissi, E.; Tai, Y. T.; Sportelli, P.; Munshi, N.; Richardson, P.; Hideshima, T.; Roodman, D. G.; Anderson, K. C.; Ghobrial, I. M. Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin. Cancer Res. 2008, 14, 865-874.
24. Francis, L. K.; Alsayed, Y.; Leleu, X.; Jia, X.; Singha, U. K.; Anderson, J.; Timm, M.; Ngo, H.; Lu, G.; Huston, A.; Ehrlich, L. A.; Dimmock, E.; Lentzsch, S.; Hideshima, T.; Roodman, G. D.; Anderson, K. C.; Ghobrial, I. M. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin. Cancer Res. 2006, 12, 6826-6835.
25. Shih, T. T.; Hou, H. A.; Liu, C. Y.; Chen, B. B.; Tang, J. L.; Chen, H. Y.; Wei, S. Y.; Yao, M.; Huang, S. Y.; Chou, W. C.; Hsu, S. C.; Tsay, W.; Yu, C. W.; Hsu, C. Y.; Tien, H. F.; Yang, P. C. Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood 2009, 113, 3161-3167.
26. Schuler, D.; Szende, B. Apoptosis in acute leukemia. Leuk. Res. 2004, 28, 661-666.
27. Del Principe, M. I.; Del Poeta, G.; Venditti, A.; Buccisano, F.; Maurillo, L.; Mazzone, C.; Bruno, A.; Neri, B.; Irno Consalvo, M.; Lo Coco, F.; Amadori, S. Apoptosis and immaturity in acute myeloid leukemia. Hematology 2005, 10, 25-34.
28. Solary, E.; Droin, N.; Bettaieb, A.; Corcos, L.; Dimanche-Boitrel, M. T.; Garrido, C. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. Leukemia 2000, 14, 1833-1849.
29. Mosser, D. D.; Morimoto, R. I. Molecular chaperones and the stress of oncogenesis. Oncogene 2004, 23, 2907-2918.
30. Samali, A.; Cotter, T. G. Heat shock proteins increase resistance to apoptosis. Exp. Cell Res. 1996, 223, 163-170. (Pubitemid 26063934)
31. Galea-Lauri, J.; Richardson, A. J.; Latchman, D. S.; Katz, D. R. Increased heat shock protein 90 (hsp90) expression leads to increased apoptosis in the monoblastoid cell line U937 following induction with TNF-alpha and cycloheximide: a possible role in immunopathology. J. Immunol. 1996, 157, 4109-4118.
32. Kondo, Y.; Kondo, S. Autophagy and cancer therapy. Autophagy 2006, 2, 85-90.
33. Agarraberes, F. A.; Dice, J. F. A molecular chaperone complex at the lysosomal membrane is required for protein translocation. J. Cell Sci. 2001, 114, 2491-2499. (Pubitemid 32684803)
34. Qing, G.; Yan, P.; Xiao, G. Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of IkappaB kinase (IKK). Cell Res. 2006, 16, 895-901. (Pubitemid 44764199)
35. Scheibel, T.; Weikl, T.; Buchner, J. Two chaperone sites in Hsp90 differing in substrate specificity and ATP dependence. Proc. Natl. Acad. Sci. USA 1998, 95, 1495-1499. (Pubitemid 28103420)
36. Workman, P.; Burrows, F.; Neckers, L.; Rosen, N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. N. Y. Acad. Sci. 2007, 1113, 202-216. (Pubitemid 350015011)
37. Zhang, H.; Burrows, F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 2004, 82, 488-499. (Pubitemid 39149859)
38. Whitesell, L.; Mimnaugh, E. G.; De Costa, B.; Myers, C. E.; Neckers, L. M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 1994, 91, 8324-8328. (Pubitemid 24273656)
39. Solit, D. B.; Chiosis, G. Development and application of Hsp90 inhibitors. Drug Discov. Today 2008, 13, 38-43.
40. Smith, V.; Sausville, E. A.; Camalier, R. F.; Fiebig, H. H.; Burger, A. M. Comparison of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother. Pharmacol. 2005, 56, 126-137.
41. Sydor, J. R.; Normant, E.; Pien, C. S.; Porter, J. R.; Ge, J.; Grenier, L.; Pak, R. H.; Ali, J. A.; Dembski, M. S.; Hudak, J.; Patterson, J.; Penders, C.; Pink, M.; Read, M. A.; Sang, J.; Woodward, C.; Zhang, Y.; Grayzel, D. S.; Wright, J.; Barrett, J. A.; Palombella, V. J.; Adams, J.; Tong, J. K. Development of 17-allylamino-17- demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc. Natl. Acad. Sci. USA 2006, 103, 17408-17413.
42. Pearl, L. H.; Prodromou, C.; Workman, P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem. J. 2008, 410, 439-453.
43. Lee, J.; Greiner, L.; Holson, E.; Slocum, K.; Ge, J.; Normant, E.; Hoyt, J.; Cushing, J.; Sydor, J.; Wright, J. IPI-493, a potent bioaviable Hsp90 inhibitor of the ansamycins class. Eur. J. Cancer 2008, Suppl,6, 49.
44. Kwon, H. J.; Yoshida, M.; Abe, K.; Horinouchi, S.; Beppu, T. Radicicol, an agent inducing the reversal of transformed phenotypes of src-transformed fibroblasts. Biosci. Biotechnol. Biochem. 1992, 56, 538-539.
45. Taldone, T.; Gozman, A.; Maharaj, R.; Chiosis, G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr. Opin. Pharmacol. 2008, 8, 370-374.
46. Drysdale, M. J.; Brough, P. A. Medicinal chemistry of Hsp90 inhibitors. Curr. Top. Med. Chem. 2008, 8, 859-868.
47. Lyons, J.; Graham, B.; Curry, J.; Reule, M.; Smyth, T.; Fazal, L.; Williams, B.; Yule, M.; Squires, M.; Thompson, N. AT13387, a fragment derived clinical candidate is active in lung and melanoma models. Eur. J. Cancer 2008, Suppl,6, 47.
48. Wettstein, D.; Baichwal, V.; Papac, D.; Cimbora, D.; McKinnon, R.; Bajji, A.; Kim, S. H.; Tangallapally, R.; Markovitz, B.; Trovato, R. MPC-3100: A non-natural product Hsp90 inhibitor witj anti-tumor activity in pre-clinical models. Eur. J. Cancer 2008, 6, Suppl., 48.
49. Lundgren, K.; Zhang, H.; Brekken, J.; Huser, N.; Powell, R. E.; Timple, N.; Busch, D. J.; Neely, L.; Sensintaffar, J. L.; Yang, Y. C.; McKenzie, A.; Friedman, J.; Scannevin, R.; Kamal, A.; Hong, K.; Kasibhatla, S. R.; Boehm, M. F.; Burrows, F. J. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol. Cancer Ther. 2009, 8, 921-929.
50. Eccles, S. A.; Massey, A.; Raynaud, F. I.; Sharp, S. Y.; Box, G.; Valenti, M.; Patterson, L.; de Haven Brandon, A.; Gowan, S.; Boxall, F.; Aherne, W.; Rowlands, M.; Hayes, A.; Martins, V.; Urban, F.; Boxall, K.; Prodromou, C.; Pearl, L.; James, K.; Matthews, T. P.; Cheung, K. M.; Kalusa, A.; Jones, K.; McDonald, E.; Barril, X.; Brough, P. A.; Cansfield, J. E.; Dymock, B.; Drysdale, M. J.; Finch, H.; Howes, R.; Hubbard, R. E.; Surgenor, A.; Webb, P.; Wood, M.; Wright, L.; Workman, P. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008, 68, 2850-2860. (Pubitemid 351556284)
51. Jensen, M. R.; Ide, S.; Brueggen, J.; Schoepfer, J.; Motwani, M.; Wang, X.; Radimerski, T.; Quadt, C.; Carcia-Echeverria, C.; Chene, P. Pharmakokinetic/pharmacodynamic relationship in human xenograft models and PBMC's treated with the Hsp90 inhibitor NVP-AUY922. Eur. J. Cancer 2008, Suppl, 6, 50.
52. Okawa, Y.; Hideshima, T.; Steed, P.; Vallet, S.; Hall, S.; Huang, K.; Rice, J.; Barabasz, A.; Foley, B.; Ikeda, H.; Raje, N.; Kiziltepe, T.; Yasui, H.; Enatsu, S.; Anderson, K. C. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 2009, 113, 846-855.
53. Nicoll, M. XL888, a novel, synthetic, orally bioaviable inhibitor of Hsp90. Eur. J. Cancer 2008, Suppl, 6, 46-47.
54. Marcu, M. G.; Neckers, L. M. The C-terminal half of heat shock protein 90 represents a second site for pharmacologic intervention in chaperone function. Curr. Cancer Drug Targets 2003, 3, 343-347.
55. Marcu, M. G.; Chadli, A.; Bouhouche, I.; Catelli, M.; Neckers, L. M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 2000, 275, 37181-37186.
56. Itoh, H.; Ogura, M.; Komatsuda, A.; Wakui, H.; Miura, A. B.; Tashima, Y. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90. Biochem. J. 1999, 343(Pt 3), 697-703. (Pubitemid 29537384)
57. Adida, C.; Recher, C.; Raffoux, E.; Daniel, M. T.; Taksin, A. L.; Rousselot, P.; Sigaux, F.; Degos, L.; Altieri, D. C.; Dombret, H. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br. J. Haematol. 2000, 111, 196-203. (Pubitemid 30832451)
58. Gyurkocza, B.; Plescia, J.; Raskett, C. M.; Garlick, D. S.; Lowry, P. A.; Carter, B. Z.; Andreeff, M.; Meli, M.; Colombo, G.; Altieri, D. C. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J. Natl. Cancer Inst. 2006, 98, 1068-1077
59. Stapnes, C.; Gjertsen, B. T.; Reikvam, H.; Bruserud, O. Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opin. Investig. Drugs 2009, 18, 433-455
60. Reynald, K.; Rowlands, M.; Hardcastle, A.; Stimson, L.; A., B.; Workman, P.; Aherne, W. Acetylation of molecular chaperones by histone deactylase inhibitors (HDACI). Eur. J. Cancer 2008, Suppl, 6, 48.
61. Bali, P.; Pranpat, M.; Bradner, J.; Balasis, M.; Fiskus, W.; Guo, F.; Rocha, K.; Kumaraswamy, S.; Boyapalle, S.; Atadja, P.; Seto, E.; Bhalla, K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 2005, 280, 26729-26734. (Pubitemid 41040705)
62. Solit, D. B.; Osman, I.; Polsky, D.; Panageas, K. S.; Daud, A.; Goydos, J. S.; Teitcher, J.; Wolchok, J. D.; Germino, F. J.; Krown, S. E.; Coit, D.; Rosen, N.; Chapman, P. B. Phase II trial of 17- allylamino-17- demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res. 2008, 14, 8302-8307.
63. Modi, S.; Stopeck, A. T.; Gordon, M. S.; Mendelson, D.; Solit, D. B.; Bagatell, R.; Ma, W.; Wheler, J.; Rosen, N.; Norton, L.; Cropp, G. F.; Johnson, R. G.; Hannah, A. L.; Hudis, C. A. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J. Clin. Oncol. 2007, 25, 5410-5417.
64. Ramanathan, R. K.; Egorin, M. J.; Eiseman, J. L.; Ramalingam, S.; Friedland, D.; Agarwala, S. S.; Ivy, S. P.; Potter, D. M.; Chatta, G.; Zuhowski, E. G.; Stoller, R. G.; Naret, C.; Guo, J.; Belani, C. P. Phase I and pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin. Cancer Res. 2007, 13, 1769-1774. (Pubitemid 46952944)
65. Ramanathan, R. K.; Trump, D. L.; Eiseman, J. L.; Belani, C. P.; Agarwala, S. S.; Zuhowski, E. G.; Lan, J.; Potter, D. M.; Ivy, S. P.; Ramalingam, S.; Brufsky, A. M.; Wong, M. K.; Tutchko, S.; Egorin, M. J. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin. Cancer Res. 2005, 11, 3385-3391.
66. Weigel, B. J.; Blaney, S. M.; Reid, J. M.; Safgren, S. L.; Bagatell, R.; Kersey, J.; Neglia, J. P.; Ivy, S. P.; Ingle, A. M.; Whitesell, L.; Gilbertson, R. J.; Krailo, M.; Ames, M.; Adamson, P. C. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin. Cancer Res. 2007, 13, 1789-1793. (Pubitemid 46952947)
67. Bagatell, R.; Gore, L.; Egorin, M. J.; Ho, R.; Heller, G.; Boucher, N.; Zuhowski, E. G.; Whitlock, J. A.; Hunger, S. P.; Narendran, A.; Katzenstein, H. M.; Arceci, R. J.; Boklan, J.; Herzog, C. E.; Whitesell, L.; Ivy, S. P.; Trippett, T. M. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17- demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin. Cancer Res. 2007, 13, 1783-1788.
68. Tse, A. N.; Klimstra, D. S.; Gonen, M.; Shah, M.; Sheikh, T.; Sikorski, R.; Carvajal, R.; Mui, J.; Tipian, C.; O'Reilly, E.; Chung, K.; Maki, R.; Lefkowitz, R.; Brown, K.; Manova-Todorova, K.; Wu, N.; Egorin, M. J.; Kelsen, D.; Schwartz, G. K. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino- 17-demethoxygeldanamycin in patients with solid tumors. Clin. Cancer Res. 2008, 14, 6704-6711.
69. Ramalingam, S. S.; Egorin, M. J.; Ramanathan, R. K.; Remick, S. C.; Sikorski, R. P.; Lagattuta, T. F.; Chatta, G. S.; Friedland, D. M.; Stoller, R. G.; Potter, D. M.; Ivy, S. P.; Belani, C. P. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin. Cancer Res. 2008, 14, 3456-3461.
70. Bruserud, O.; Stapnes, C.; Ersvaer, E.; Gjertsen, B. T.; Ryningen, A. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr. Pharm. Biotechnol. 2007, 8, 388-400. (Pubitemid 350268198)
71. de Bono, J. S.; Kristeleit, R.; Tolcher, A.; Fong, P.; Pacey, S.; Karavasilis, V.; Mita, M.; Shaw, H.; Workman, P.; Kaye, S.; Rowinsky, E. K.; Aherne, W.; Atadja, P.; Scott, J. W.; Patnaik, A. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein 90 inhibitory profile, in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14, 6663-6673.
72. Bug, G.; Ritter, M.; Wassmann, B.; Schoch, C.; Heinzel, T.; Schwarz, K.; Romanski, A.; Kramer, O. H.; Kampfmann, M.; Hoelzer, D.; Neubauer, A.; Ruthardt, M.; Ottmann, O. G. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005, 104, 2717-2725. (Pubitemid 41798282)
73. Clarke, P. A.; Welsh, L.; Valenti, M.; Eccles, S. A.; Workman, P. Hsp90 inhibitors target addiction to mutant oncoproteins in colorectal cancer. Eur. J. Cancer 2008, Suppl, 6, 47.
74. Chatterjee, M.; Jain, S.; Stuhmer, T.; Andrulis, M.; Ungethum, U.; Kuban, R. J.; Lorentz, H.; Bommert, K.; Topp, M.; Kramer, D.; Muller-Hermelink, H. K.; Einsele, H.; Greiner, A.; Bargou, R. C. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 2007, 109, 720-728.
75. Lin, K.; Rockliffe, N.; Johnson, G. G.; Sherrington, P. D.; Pettitt, A. R. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Oncogene 2008, 27, 2445-2455.
76. Bao, R.; Lai, C. J.; Qu, H.; Wang, D.; Yin, L.; Zifcak, B.; Atoyan, R.; Wang, J.; Samson, M.; Forrester, J.; Dellarocca, S.; Xu, G. X.; Tao, X.; Zhai, H. X.; Cai, X.; Qian, C. CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy. Clin. Cancer Res. 2009, 15(12), 4046-4057.
77. Powers, M. V.; Clarke, P. A.; Workman, P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008, 14, 250-262.
78. Sullivan, W. P.; Owen, B. A.; Toft, D. O. The influence of ATP and p23 on the conformation of hsp90. J. Biol. Chem. 2002, 277, 45942-45948.
79. Solit, D. B.; Ivy, S. P.; Kopil, C.; Sikorski, R.; Morris, M. J.; Slovin, S. F.; Kelly, W. K.; DeLaCruz, A.; Curley, T.; Heller, G.; Larson, S.; Schwartz, L.; Egorin, M. J.; Rosen, N.; Scher, H. I. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin. Cancer Res. 2007, 13, 1775-1782. (Pubitemid 46952945)
80. Fritz, C.; Tillotson, B.; Ge, J.; Normant, E.; Depew, K.; Basuki, J.; Hafeez, N.; Patterson, J.; Porter, J. R.; Palombella, V. Comparison of the cellular and biochemical properties of ansamycin and nonansamycin based Hsp90 inhibitors. Eur. J. Cancer 2008, Suppl, 6, 48.
81. Guo, W.; Reigan, P.; Siegel, D.; Zirrolli, J.; Gustafson, D.; Ross, D. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol. Pharmacol. 2006, 70, 1194-1203. (Pubitemid 44435970)
82. Germain, R. N.; Jenkins, M. K. In vivo antigen presentation. Curr. Opin. Immunol. 2004, 16, 120-125.
83. Callahan, M. K.; Garg, M.; Srivastava, P. K. Heat-shock protein 90 associates with N-terminal extended peptides and is required for direct and indirect antigen presentation. Proc. Natl. Acad. Sci. USA 2008, 105, 1662-1667.
84. Rajagopal, D.; Bal, V.; Mayor, S.; George, A.; Rath, S. A role for the Hsp90 molecular chaperone family in antigen presentation to T lymphocytes via major histocompatibility complex class II molecules. Eur. J. Immunol. 2006, 36, 828-841.
85. Bae, J.; Mitsiades, C.; Tai, Y. T.; Bertheau, R.; Shammas, M.; Batchu, R. B.; Li, C.; Catley, L.; Prabhala, R.; Anderson, K. C.; Munshi, N. C. Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J. Immunol. 2007, 178, 7730-7737.
86. Schnaider, T.; Somogyi, J.; Csermely, P.; Szamel, M. The Hsp90- specific inhibitor, geldanamycin, blocks CD28-mediated activation of human T lymphocytes. Life Sci. 1998, 63, 949-954. (Pubitemid 28392039)
87. Schnaider, T.; Somogyi, J.; Csermely, P.; Szamel, M. The Hsp90- specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation. Cell Stress Chaperones 2000, 5, 52-61. (Pubitemid 30099056)
88. Yorgin, P. D.; Hartson, S. D.; Fellah, A. M.; Scroggins, B. T.; Huang, W.; Katsanis, E.; Couchman, J. M.; Matts, R. L.; Whitesell, L. Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases. J. Immunol. 2000, 164, 2915-2923. (Pubitemid 30148948)
89. Piatelli, M. J.; Doughty, C.; Chiles, T. C. Requirement for a hsp90 chaperone-dependent MEK1/2-ERK pathway for B cell antigen receptor- induced cyclin D2 expression in mature B lymphocytes. J. Biol. Chem. 2002, 277, 12144-12150.
90. Chant, I. D.; Rose, P. E.; Morris, A. G. Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry. Br. J. Haematol. 1995, 90, 163-168.
91. Thomas, X.; Campos, L.; Mounier, C.; Cornillon, J.; Flandrin, P.; Le, Q. H.; Piselli, S.; Guyotat, D. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk. Res. 2005, 29, 1049-1058. (Pubitemid 40982599)
92. Flandrin, P.; Guyotat, D.; Duval, A.; Cornillon, J.; Tavernier, E.; Nadal, N.; Campos, L. Significance of heat-shock protein (HSP: ) 90 expression in acute myeloid leukemia cells. Cell Stress Chaperones 2008, 13, 357-364.
93. Duval, A.; Olaru, D.; Campos, L.; Flandrin, P.; Nadal, N.; Guyotat, D. Expression and prognostic significance of heat-shock proteins in myelodysplastic syndromes. Haematologica 2006, 91, 713-714. (Pubitemid 43799480)
94. Baldus, C. D.; Mrozek, K.; Marcucci, G.; Bloomfield, C. D. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. Br. J. Haematol. 2007, 137, 387-400.
95. Knapper, S. FLT3 inhibition in acute myeloid leukaemia. Br. J. Haematol. 2007, 138, 687-699. (Pubitemid 47313203)
96. Nakao, M.; Yokota, S.; Iwai, T.; Kaneko, H.; Horiike, S.; Kashima, K.; Sonoda, Y.; Fujimoto, T.; Misawa, S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10, 1911-1918. (Pubitemid 27019637)
97. Yamamoto, Y.; Kiyoi, H.; Nakano, Y.; Suzuki, R.; Kodera, Y.; Miyawaki, S.; Asou, N.; Kuriyama, K.; Yagasaki, F.; Shimazaki, C.; Akiyama, H.; Saito, K.; Nishimura, M.; Motoji, T.; Shinagawa, K.; Takeshita, A.; Saito, H.; Ueda, R.; Ohno, R.; Naoe, T. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001, 97, 2434-2439. (Pubitemid 32291491)
98. Yao, Q.; Weigel, B.; Kersey, J. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clin. Cancer Res. 2007, 13, 1591-1600. (Pubitemid 46450452)
99. Bruserud, O.; Ryningen, A.; Olsnes, A. M.; Stordrange, L.; Oyan, A. M.; Kalland, K. H.; Gjertsen, B. T. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007, 92, 332-341.
100. Reikvam, H.; Olsnes, A.; Gjertsen, B. T.; Ersvaer, E. M.; Bruserud, O. Nuclear Factor-κB signalling - a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia. Crit. Rev. Oncog. 2009, In press.
101. Citri, A.; Harari, D.; Shohat, G.; Ramakrishnan, P.; Gan, J.; Lavi, S.; Eisenstein, M.; Kimchi, A.; Wallach, D.; Pietrokovski, S.; Yarden, Y. Hsp90 recognizes a common surface on client kinases. J. Biol. Chem. 2006, 281, 14361-14369. (Pubitemid 43848365)
102. Grosjean-Raillard, J.; Ades, L.; Boehrer, S.; Tailler, M.; Fabre, C.; Braun, T.; De Botton, S.; Israel, A.; Fenaux, P.; Kroemer, G. Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Apoptosis 2008, 13, 1148-1161.
103. Shimada, M.; Nakanishi, M. DNA damage checkpoints and cancer. J. Mol. Histol. 2006, 37, 253-260.
104. Chen, Y.; Poon, R. Y. The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability. Front. Biosci. 2008, 13, 5016-5029.
105. Amico, D.; Barbui, A. M.; Erba, E.; Rambaldi, A.; Introna, M.; Golay, J. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood 2003, 101, 4589-4597. (Pubitemid 36857832)
106. Didier, C.; Cavelier, C.; Quaranta, M.; Galcera, M. O.; Demur, C.; Laurent, G.; Manenti, S.; Ducommun, B. G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress. Oncogene 2008, 27, 3811-3820. (Pubitemid 351862053)
107. Arlander, S. J.; Eapen, A. K.; Vroman, B. T.; McDonald, R. J.; Toft, D. O.; Karnitz, L. M. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J. Biol. Chem. 2003, 278, 52572-52577.
108. Mesa, R. A.; Loegering, D.; Powell, H. L.; Flatten, K.; Arlander, S. J.; Dai, N. T.; Heldebrant, M. P.; Vroman, B. T.; Smith, B. D.; Karp, J. E.; Eyck, C. J.; Erlichman, C.; Kaufmann, S. H.; Karnitz, L. M. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 2005, 106, 318-327.
109. Izquierdo, M. A.; Shoemaker, R. H.; Flens, M. J.; Scheffer, G. L.; Wu, L.; Prather, T. R.; Scheper, R. J. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int. J. Cancer 1996, 65, 230-237. (Pubitemid 26051685)
110. Kasimir-Bauer, S.; Beelen, D.; Flasshove, M.; Noppeney, R.; Seeber, S.; Scheulen, M. E. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and longterm survival in patients with de novo acute myeloid leukemia. Exp. Hematol. 2002, 30, 1302-1308.
111. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425, 407-410.
112. Munster, P. N.; Marchion, D. C.; Basso, A. D.; Rosen, N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res. 2002, 62, 3132-3137. (Pubitemid 34602405)
113. Fiskus, W.; Rao, R.; Fernandez, P.; Herger, B.; Yang, Y.; Chen, J.; Kolhe, R.; Mandawat, A.; Wang, Y.; Joshi, R.; Eaton, K.; Lee, P.; Atadja, P.; Peiper, S.; Bhalla, K. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood 2008, 112, 2896-2905.
114. Yu, W.; Rao, Q.; Wang, M.; Tian, Z.; Lin, D.; Liu, X.; Wang, J. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level. Leuk. Res. 2006, 30, 575-582. (Pubitemid 43374587)
115. Bruserud, O.; Hovland, R.; Wergeland, L.; Huang, T. S.; Gjertsen, B. T. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 2003, 88, 416-428.
116. Meyer, P. N.; Roychowdhury, S.; Kini, A. R.; Alkan, S. HSP90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells. Leuk. Res. 2008, 32, 143-149. (Pubitemid 350100847)
117. Wetzler, M.; Earp, J. C.; Brady, M. T.; Keng, M. K.; Jusko, W. J. Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity - pharmacodynamic drug-drug interaction modeling. Clin. Cancer Res. 2007, 13, 2261-2270.
118. Al Shaer, L.; Walsby, E.; Gilkes, A.; Tonks, A.; Walsh, V.; Mills, K.; Burnett, A.; Rowntree, C. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. Br. J. Haematol. 2008, 141, 483-493. (Pubitemid 351550553)
119. George, P.; Bali, P.; Cohen, P.; Tao, J.; Guo, F.; Sigua, C.; Vishvanath, A.; Fiskus, W.; Scuto, A.; Annavarapu, S.; Moscinski, L.; Bhalla, K. Cotreatment with 17-allylaminodemethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res. 2004, 64, 3645-3652. (Pubitemid 38657944)
120. Kamynina, E.; Kauppinen, K.; Duan, F.; Muakkassa, N.; Manor, D. Regulation of proto-oncogenic dbl by chaperone-controlled, ubiquitin- mediated degradation. Mol. Cell Biol. 2007, 27, 1809-1822. (Pubitemid 46310045)
121. Rao, R.; Fiskus, W.; Yang, Y.; Lee, P.; Joshi, R.; Fernandez, P.; Mandawat, A.; Atadja, P.; Bradner, J. E.; Bhalla, K. HDAC6 inhibition enhances 17-AAG - mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008, 112, 1886-1893.
122. Inoue, S.; Mai, A.; Dyer, M. J.; Cohen, G. M. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2006, 66, 6785-6792.
123. Nishioka, C.; Ikezoe, T.; Yang, J.; Takeuchi, S.; Koeffler, H. P.; Yokoyama, A. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leuk. Res. 2008, 32, 1382-1392.
124. Fiedler, W.; Serve, H.; Dohner, H.; Schwittay, M.; Ottmann, O. G.; O'Farrell, A. M.; Bello, C. L.; Allred, R.; Manning, W. C.; Cherrington, J. M.; Louie, S. G.; Hong, W.; Brega, N. M.; Massimini, G.; Scigalla, P.; Berdel, W. E.; Hossfeld, D. K. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005, 105, 986-993.
125. Fiedler, W.; Mesters, R.; Tinnefeld, H.; Loges, S.; Staib, P.; Duhrsen, U.; Flasshove, M.; Ottmann, O. G.; Jung, W.; Cavalli, F.; Kuse, R.; Thomalla, J.; Serve, H.; O'Farrell, A. M.; Jacobs, M.; Brega, N. M.; Scigalla, P.; Hossfeld, D. K.; Berdel, W. E. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003, 102, 2763-2767.
126. Rizzieri, D. A.; Feldman, E.; Dipersio, J. F.; Gabrail, N.; Stock, W.; Strair, R.; Rivera, V. M.; Albitar, M.; Bedrosian, C. L.; Giles, F. J. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 2008, 14, 2756-2762.
127. Yee, K. W.; Zeng, Z.; Konopleva, M.; Verstovsek, S.; Ravandi, F.; Ferrajoli, A.; Thomas, D.; Wierda, W.; Apostolidou, E.; Albitar, M.; O'Brien, S.; Andreeff, M.; Giles, F. J. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 2006, 12, 5165-5173.
128. Kojima, K.; Shimanuki, M.; Shikami, M.; Samudio, I. J.; Ruvolo, V.; Corn, P.; Hanaoka, N.; Konopleva, M.; Andreeff, M.; Nakakuma, H. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 2008, 22, 1728-1736.
129. Kojima, K.; Shimanuki, M.; Shikami, M.; Andreeff, M.; Nakakuma, H. Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci. 2009, 100, 1128-1136.
130. Oyan, A. M.; Anensen, N.; Bo, T. H.; Stordrange, L.; Jonassen, I.; Bruserud, O.; Kalland, K. H.; Gjertsen, B. T. Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer 2009, 9, 77.
131. Gocke, C. D.; Reaman, G. H.; Stine, C.; Zhang, M. Y.; Osmani, S. A.; Miller, B. A. The nuclear migration gene NudC and human hematopoiesis. Leuk. Lymphoma 2000, 39, 447-454. (Pubitemid 32162384)
132. Tronstad, K. J.; Bruserud, O.; Berge, K.; Berge, R. K. Antiproliferative effects of a non-beta-oxidizable fatty acid, tetradecylthioacetic acid, in native human acute myelogenous leukemia blast cultures. Leukemia 2002, 16, 2292-2301.
133. Kawai, M.; Chen, J.; Cheung, C. Y.; Chang, T. K. Transcript profiling of cytochrome P450 genes in HL-60 human leukemic cells: upregulation of CYP1B1 by all-trans-retinoic acid. Mol. Cell Biochem. 2003, 248, 57-65.
134. Anensen, N.; Oyan, A. M.; Bourdon, J. C.; Kalland, K. H.; Bruserud, O.; Gjertsen, B. T. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin. Cancer Res. 2006, 12, 3985-3992.
135. Anensen, N.; Haaland, I.; D'Santos, C.; Van Belle, W.; Gjertsen, B. T. Proteomics of p53 in diagnostics and therapy of acute myeloid leukemia. Curr. Pharm. Biotechnol. 2006, 7, 199-207. (Pubitemid 43881083)
136. Irish, J. M.; Hovland, R.; Krutzik, P. O.; Perez, O. D.; Bruserud, O.; Gjertsen, B. T.; Nolan, G. P. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004, 118, 217-228. (Pubitemid 38962577)
137. Yamaguchi, T.; Ye, C.; Chattopadhyay, N.; Sanders, J. L.; Vassilev, P. M.; Brown, E. M. Enhanced expression of extracellular calcium sensing receptor in monocyte-differentiated versus undifferentiated HL-60 cells: potential role in regulation of a nonselective cation channel. Calcif. Tissue Int. 2000, 66, 375-382.
138. Wenandy, L.; Kollgaard, T.; Letsch, A.; Andersen, R. S.; Stather, D.; Seremet, T.; Svane, I. M.; Vindelov, L.; Andersen, M. H.; Thor Straten, P. The 1170 A-P single-nucleotide polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility antigen (mHag). Leukemia 2009, [Epub ahead of print].
139. Frostad, S.; Bruserud, O. In vitro effects of insulin-like growth factor-1 (IGF-1) on proliferation and constitutive cytokine secretion by acute myelogenous leukemia blasts. Eur. J. Haematol. 1999, 62, 191-198. (Pubitemid 29111485)
140. Tabe, Y.; Jin, L.; Tsutsumi-Ishii, Y.; Xu, Y.; McQueen, T.; Priebe, W.; Mills, G. B.; Ohsaka, A.; Nagaoka, I.; Andreeff, M.; Konopleva, M. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res. 2007, 67, 684-694. (Pubitemid 46192208)
141. Xiang, Z.; Zhao, Y.; Mitaksov, V.; Fremont, D. H.; Kasai, Y.; Molitoris, A.; Ries, R. E.; Miner, T. L.; McLellan, M. D.; DiPersio, J. F.; Link, D. C.; Payton, J. E.; Graubert, T. A.; Watson, M.; Shannon, W.; Heath, S. E.; Nagarajan, R.; Mardis, E. R.; Wilson, R. K.; Ley, T. J.; Tomasson, M. H. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 2008, 111, 4809-4812.
142. Soupir, C. P.; Vergilio, J. A.; Dal Cin, P.; Muzikansky, A.; Kantarjian, H.; Jones, D.; Hasserjian, R. P. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am. J. Clin. Pathol. 2007, 127, 642-650. (Pubitemid 46587480)
143. Chim, C. S.; Wong, A. S.; Kwong, Y. L. Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias. Ann. Hematol. 2003, 82, 738-742.
144. Ersvaer, E.; Zhang, J. Y.; McCormack, E.; Olsnes, A.; Anensen, N.; Tan, E. M.; Gjertsen, B. T.; Bruserud, O. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. Eur. J. Haematol. 2007, 79, 210-225. (Pubitemid 47231163)
145. Aggerholm, A.; Hokland, P. DAP-kinase CpG island methylation in acute myeloid leukemia: methodology versus biology? Blood 2000, 95, 2997-2999.
146. Schmidt, C. A.; Oettle, H.; Ludwig, W. D.; Serke, S.; Pawlaczyk- Peter, B.; Wilborn, F.; Binder, L. T.; Huhn, D.; Siegert, W. Overexpression of the Raf-1 proto-oncogene in human myeloid leukemia. Leuk. Res. 1994, 18, 409-413. (Pubitemid 24169822)
147. Kuittinen, O.; Savolainen, E. R.; Koistinen, P.; Turpeenniemi- Hujanen, T. Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML. Anticancer Res. 1999, 19, 4395-4400.
148. Roth, A.; Vercauteren, S.; Sutherland, H. J.; Lansdorp, P. M. Telomerase is limiting the growth of acute myeloid leukemia cells. Leukemia 2003, 17, 2410-2417. (Pubitemid 38072579)
149. Coulthard, S. A.; Howell, C.; Robson, J.; Hall, A. G. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. Blood 1998, 92, 2856-2862.
150. Olwill, S. A.; McGlynn, H.; Gilmore, W. S.; Alexander, H. D. Annexin II cell surface and mRNA expression in human acute myeloid leukaemia cell lines. Thromb. Res. 2005, 115, 109-114.
151. Pillozzi, S.; Brizzi, M. F.; Balzi, M.; Crociani, O.; Cherubini, A.; Guasti, L.; Bartolozzi, B.; Becchetti, A.; Wanke, E.; Bernabei, P. A.; Olivotto, M.; Pegoraro, L.; Arcangeli, A. HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia 2002, 16, 1791-1798. (Pubitemid 35050110)
152. Fatrai, S.; Schepers, H.; Tadema, H.; Vellenga, E.; Daenen, S. M.; Schuringa, J. J. Mucin1 expression is enriched in the human stem cell fraction of cord blood and is upregulated in majority of the AML cases. Exp. Hematol. 2008, 36, 1254-1265.
153. Smadja, D. M.; Laurendeau, I.; Avignon, C.; Vidaud, M.; Aiach, M.; Gaussem, P. The angiopoietin pathway is modulated by PAR-1 activation on human endothelial progenitor cells. J. Thromb. Haemost. 2006, 4, 2051-2058. (Pubitemid 44226788)